The BC Cancer Foundation has launched a $6.8 million fundraising campaign to expand provincial immunotherapy research program ...

The foundation hopes to put the funds toward two clinical programs in blood cancers and one preclinical project in solid tumors.

MaxCyte's technology will support TG Therapeutics' efforts to develop a CD19 CAR-T cell therapy program for autoimmune diseases.

Acute Myeloid Leukemia (AML) is a hematological malignancy characterized by the rapid, uncontrolled growth of immature myeloid cells, leading to bone marrow ...

A research team has made a major discovery on how the CUL5 gene affects CAR-T cell therapy, an advanced cancer therapy. The study reveals that reducing the activity of the CUL5 gene helps CAR-T cells ...

The FDA has granted Fast Track designation to ADI-001 for the treatment of refractory systemic lupus erythematosus with extrarenal involvement.

BRANFORD, Conn., Feb. 11, 2025 (GLOBE NEWSWIRE) -- EvolveImmune Therapeutics, an immunotherapy company developing first-in-category, multifunctional T Cell engager biotherapeutics to address unmet ...

Immunotherapy revolutionises cancer treatment by harnessing the immune system, offering targeted therapy with fewer side ...

In oncology, immunotherapy stands as a transformative approach for treating solid tumors, notably through pioneering treatments like immune checkpoint ...

Inc. (Nasdaq: TSVT) today provided full-year Abecma® (idecabtagene vicleucel; ide-cel) sales results for 2024, in partnership with Brist ...